Allegations Against Capricor Therapeutics Lead to Class Action Notice for Affected Shareholders

Class Action Alert: Capricor Therapeutics, Inc. Shareholders

In recent developments, shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) who have encountered financial losses due to the company's recent performance are encouraged to get in touch with The Gross Law Firm. The firm has put out a notification aimed at informing these shareholders about a prospective class action lawsuit that is currently unfolding.

Background on Capricor Therapeutics

Capricor Therapeutics, a company specializing in regenerative medicine, recently faced significant scrutiny regarding their lead drug therapy, deramiocel, intended for treating cardiomyopathy linked to Duchenne muscular dystrophy (DMD). Despite prior optimistic statements regarding the FDA's approval processes and the overall efficacy of their drug, recent communications from the company have raised alarms among investors.

Allegations and Class Period

The allegations stem from statements made by Capricor's management during the class period, which began on October 9, 2024, and continued through July 10, 2025. Claims of positive developments surrounding the Biologics License Application (BLA) for deramiocel were later contradicted when Capricor announced that they had received a Complete Response Letter (CRL) from the FDA. This letter pointed out deficiencies in the application and indicated that the data provided was insufficient to demonstrate effectiveness, hence delaying approval processes.

As a consequence of this news, the price of Capricor's stock saw a significant decline – plummeting from $11.40 per share on July 10, 2025, to a mere $7.64 on July 11, 2025. This drastic drop has left many shareholders looking for answers and recourse.

Next Steps for Affected Shareholders

Shareholders who believe they have suffered losses during this class period are urged to act promptly. The Gross Law Firm is offering their services to assist these investors, and importantly, an appointment as a lead plaintiff is optional for those wishing to seek recovery. Potential plaintiffs are encouraged to register their information before the deadline on September 15, 2025, to ensure they are included in case developments moving forward.

Once registered, shareholders will also benefit from portfolio monitoring software, which will deliver updates throughout the litigation process.

Why Reach Out to The Gross Law Firm?

The Gross Law Firm is recognized nationally for its commitment to defending the rights of investors impacted by fraudulent practices. They emphasize the importance of corporate accountability and strive to help shareholders recuperate funds lost through misleading or false information. Their experienced team is poised to navigate the complexities of securities litigation and advocate for the interests of investors.

Affected individuals can make contact through a dedicated link to the law firm's submission form or by reaching out via their office details listed below.

Contact Information

The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Given the significant implications of the recent developments surrounding Capricor Therapeutics, it is vital for shareholders to stay informed and actively engage in understanding their rights and recovery options through appropriate legal channels.